化合物JD5037 T4453

Product Introduction
Bioactivity


英文名: JD-5037

描述: JD-5037 是一种 CB1R 有效拮抗剂，IC50=1.5 nM。

动物实验: Mice: JD-5037 is formulated in vehicle (V; 1% Tween80, 4% DMSO, 95% Saline). Obese mice are treated chronically (28 d) with vehicle (V; 1% Tween80, 4% DMSO, 95% Saline), JD5037, or SLV319 at a dose of 3 mg/kg, i.p. Body weight and food intake are monitored daily. Mice are euthanized by cervical dislocation under anesthesia; the brain, hypothalamus, liver, and combined fat pads are removed, weighed, and snap-frozen, and trunk blood is collected for determining the endocrine and biochemical parameters

体内活性: JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia as well as reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (87.33 mM)


关键字: Cannabinoid Receptor | JD5037 | inhibit | JD-5037 | Inhibitor

相关产品: PrNMI | Taranabant racemate | Hemopressin(human, mouse) TFA | MJ 15 | Hemopressin (rat) acetate(568588-77-2 free base) | LY2828360 | 2,3-Butanediol | CB1R/AMPK modulator 1 | Virodhamine | PSNCBAM-1

相关库: Membrane Protein-targeted Compound Library | Anti-Metabolism Disease Compound Library | Bioactive Compounds Library Max | Neuronal Signaling Compound Library | GPCR Compound Library | Inhibitor Library | Anti-Obesity Compound Library | Anti-Diabetic Compound Library | Anti-Fibrosis Compound Library | Preclinical Compound Library

化合物JD5037 T4453信息由TargetMol中国为您提供，如您想了解更多关于化合物JD5037 T4453报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途